cost for pertuzab in the us
Overall survival is a secondary endpoint of the CLEOPATRA study [13]. 23/06/2012 22:28:00. Jun 12: Pertuzumab will be sold as Perjeta in the US at a cost of $5,900 a month, or about $71,000 a year [12].un 12: Launched in the US [14]. 06/12/2012 15:20:34. Jun 12: Perjeta is approved in the US in combination with trastuzumab and docetaxel chemotherapy for the treatment of people with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease [11}.